UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.